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INTRODUCTION 
                               
One  of  the  greatest  tragedies  in  modern  world  is  the  rise  in 
the viral  infections  causing  epidemics  and  pandemics claiming  
thousands  of lives.  Adding  to  the  problem  is  the  lack  of specific  
treatment  in  most  of these  diseases.  So  the  only  option  that  leaves  
is  the  accurate  and  early  diagnosis  of  these  diseases. 
One  such  disease  is  the  Dengue  fever  caused  by  Dengue  
virus.  Came  into  limelight  just  about  5o  years  back,  the  disease  is  
now  prevalent  in  more  than  100  countries  causing  mortality  and  
morbidity  year  after  year1.  The  incidence  of dengue  in  endemic  
countries  is around  50  million  annually2.  At  any  given  time  about  
40%  of  the world’s   population  is  at  risk  of  acquiring  dengue  
infection.  In 2005  the  world  health  assembly  revised  the international  
health  regulations  adding dengue to  the  list  of  disease  of  public  
health  emergencies  due  to  the  rapid  spread  of  the  disease. 
Dengue fever produces a wide spectrum of  disease   
manifestations  ranging  from  mild  febrile  illness  to  severe  forms  like  
dengue  hemorrhagic  fever  and  dengue  shock  syndrome.  So  the  main  
challenge  a  physician  faces  in  an  epidemic  of  dengue  is  monitoring  
of  patients  to  look  for early  signs  of  deterioration. It  has  been  
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possible  by  means  of  an  array of   laboratory  investigations.                        
Plasma  leakage  is  the  most  common  internal  abnormality   associated  
with  dengue   infection  and  most  complications  are  directly 
proportional  to  the  severity  of  plasma  leakage.  There are  several  
methods  to  assess  plasma  leakage.  One  of  them  is  the  increase  in  
gall   bladder  wall  thickness  which  has  direct  correlation  with  
severity  of  plasma  leakage  according  to  many  studies  done  
elsewhere.  The best  advantage  of  this  is  method  is  that  it  is  a  
cheap  and  quick  method  and  also  it  can be  done  as  a routine  bed-
side  test.  The  procedure  is  a painless  and non-invasive  method  and  
it  can also  look  into  other  organs  like pleura  for  pleural  effusion  
and  kidneys  for  peri-nephric  collection  all  adding  to  better  
prognostification  of  the  disease  and better  patient  care. 
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AIMS AND OBJECTIVES 
 
1. To evaluate the role of increase in gall bladder thickness in dengue 
fever. 
 
2. To correlate the increased gall bladder thickness with dengue 
severity and prognosis. 
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REVIEW OF LITERATURE 
History of dengue 
             Dengue is  an  age  old  disease. There  has  been  hieroglyphics  
from  ancient  Egypt  of  2000 yrs mentioning  of  dengue  like  illness  
spread  by  mosquitoes  as  curse  of  Gods.  Chinese  manuscripts of  the  
4th  century  mentions  about  the  “water  disease” associated  with  flying   
and  biting  insects  causing  fever  and  joint  pains   and  bleeding  
manifestations3.  This  is  perhaps  the  first  record  of  dengue.                       
The  first  outbreak  of dengue  in  the   new  world  took  place   in  the  
French  West  Indies  and  Panama  in the  17th  century.  As  the  
exploration  by  sea  became  common  mosquitoes  and  human  carriers  
helped  to  carry  the  disease  to  different  parts  of  the  world.  The  
word   dengue  came  from  the  word  Ka-dingapepo  called  the  disease  
of  the   devil.  It  was  called  as  breakbone  fever  by  Benjamin  Rush  
who  first   reported  the  disease  by clinical  methods and  he  called  it 
so  because  of   the  severe  arthralgia  and  myalgia  associated  with  the 
disease. 
Beyond  origins  and  geography  the  disease  has  now  become  a  
pandemic  and  is  a  great  threat  to  health  care.  The  first  pandemic  
of  dengue  occurred  in south  east  Asia  and  since  regular  outbreaks  
are  happening  year  by  year.  4The  first  case  of  dengue  in India  was  
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reported  in 1946  in Calcutta  and  the  first  epidemic  occurred  in 1963-
1964. 
 
 
 
Dengue- Global scenario 
It  is  now  an  established  fact  that  dengue  is  a  worldwide 
concern,  but  south east Asia  is  the  hot  spot  of  the  disease.  The  
disease  which  was   previously limited to few countries is now  endemic  
in 110  countries.  Cases  in  Americas,  SE Asia, and western pacific 
exceeded 1.2 million in 2008 and in 2013 it  is  over  3 million5. Now  
outbreaks  of Dengue  exists  even  in  European  countries. About 
500,000 cases of severe  
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dengue are  reported  each year  of  which  2.5%  die, the major  
proportion of them  being  children6. 
Dengue-Indian Scenario 
          The  first  case  of  dengue  was  reported  in Chennai in  1780  and  
the  virus  was  isolated  in  Kolkata  in 1944 in  US  soldiers6. The 
dengue  hemorrhagic  fever  started  showing  up  in  1988  and  first  
epidemic  in 1996.  Since  there  has  been  recurrent outbreaks  in India. 
Highest  outbreak  occurred  in  2015  with  reported  cases  of 90,000  
and  deaths  of 1807. 
Year wise Dengue cases in India 
  
 
Year Cases Death 
2009 15500 96 
2010 28300 110 
2011 18860 160 
2012 50200 240 
2013 75800 195 
2014 40570 140 
2015 90040 180 
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Distribution of dengue in India8 
 
The virus 
The  virus  is  an  Arbovirus  belonging  to  genus  Flaviviridae9. It  
is  a  single  stranded  RNA  virus.  It  has  4  serotypes DENV-1,2,3 
and4.   
Serotype 2  is  associated  with  severe  form  of  dengue  infection.  
All 4  types  are  prevalent  in India.  Infection  with  1  serotype  does not  
confer  immunity  against  another.  A  dengue  re-infection  is  attributed  
with  more  severe  form  of   dengue. 
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The vector 
Aedes Aegypti   is the  main  vector  of  dengue virus. Dengue 
infection is  maintained  through  a  human-mosquito-human cycle  where 
human  is  the  amplifying  host. 10After  biting  a  carrier  human  there  
is  an  extrinsic  incubation  period  of  8-12  days  after  which  the  
mosquito  can  remain  infective  throughout  its  life.  There  is  also  
supportive  evidence  of  transovarian  transmission  of  virus  in  
mosquitoes. 
 
 
9 
 
The host 
The  incubation  period  is  4  to  10  days  after  which  a  wide  
spectrum of disease appears. The host immunity plays a major role in the 
pathogenesis of dengue fever. The disease has a more indolent course in 
children and young adults as plasma leakage is more severe in them. 
Infection with one serotype confers lifelong immunity to that serotype. 
Individual risk factors like secondary dengue, cardiac diseases, bronchial 
asthma, diabetes mellitus, sickle cell anaemia have higher morbidity and 
mortality. 
Pathogenesis of dengue11 
 
 
 
10 
 
Replication of dengue and infection cycle12 
 
Dengue virus attaches to the cell wall of the human being 
 
 
Cell membrane folds around the virus a pouch is formed 
 
 
Virus will be sealed.The pouch is called endosome 
 
 
Viral particle will be released into cell cytoplasm 
 
 
Nucleocapsid opens to uncoat the viral genome and viral RNA will 
will be released 
 
 
Viral RNA uses host cell machinery for its replication 
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Viral RNA uses host ribosomes present on the ER 
                It will be translated into viral RNA and viral polypeptide 
 
                The viral polypeptide is made into viral proteins 
 
                Viral RNA is coated by nucleocapsid containing C protein 
 
                                   Nucleocapsid enters into ER 
 
           Nucleocapsid will be surrounded by E and M protein 
                       
                        Immature viral particles are formed 
                    
                 Immature viruses are transmitted through golgi network 
            
                Immature virus becomes matured viruses and are released 
                  
                             These virus affects new host cells 
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Skewed T cell response 
       In some persons dengue infection causes an altered T cell 
response13. The heightened response is mediated through memory T cells 
especially in dengue re-infection. The alterd response causes a cytokine 
storm causing capillary leakage and severe dengue disease. 
Factor affecting dengue severity 
1) antibodies dependent enhancement 
       The most accepted theory for dengue infection is the Halstead 
hypothesis. According to this theory a patient suffering from a re-
infection of dengue has higher risk of DHF and DSS. Pre-existing 
antibodies from previous infection recognizes the infective virus and 
forms antigen-antibody complex, which is binds to Fc receptor of 
immunoglobulins. This cause the mononuclear cells to release vasoactive 
mediators that in turn causes increased vascular permeability. 
2) Compliment activation 
       Compliment activation also plays a major part in severe dengue as 
evidenced by an increased compliment C3a and C5a in DSS14. The NS1 
antigen is primarily responsible for compliment activation.. 
3) Non structural 1(NS1) 
       It was first detected in dengue cell cultures and later was found to 
circulate as complexes wit thombin and prothrombin elevating aPTT. It 
also activates compliment pathway. 
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4) Cytotoxic factor 
       It is produced by CD4+T cells and it kills CD4+T cells and 
macrophages and cause immune suppression. It has been found that 
people with DHF have high concentratons of CF in serum. CF is specific 
for dengue virus and hence can be used in diagnosis. 
5) Host genetic factors 
      Some host genetic factors have its role to play in dengue infection. 
G6PD infection is found to be associated with higher incidence if DHF. 
15Polymorphism in TNFα, CTLA-4, TGF-β, JAk1 genes all are associated 
with DHF/DSS. AB blood group has high resistance to dengue fever and 
DSS. 
6) Influence of age 
     Children are more prone to severe forms of dengue. In infants even 
primary dengue can cause DSS/DHF. 
7) Effects of malnutrition 
      Malnourishment either over or under nourishment is adversely 
affected in dengue. 
8) Influence of race 
      More severe in Cuban, African, Caribbean, mongoloid races less in 
Caucasians. 
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9) Auto immunity cross reaction 
       Antibodies formed during dengue like anti NS1 antibody has been 
found it cross with cells of liver, endothelial cells, and platelets and in 
production of nitric oxide and IL-6 and may be responsible for plasma 
leakage. 
10) Viral factors 
         Dengue severity has been shown to vary according to the serotypes 
of the virus. DENV type 2 is known to be associated with severe forms of 
the disease. DENV type 1 has low mortality but high morbidity. 
Sequential infection and time interval between primary infection and 
secondary are factors that play an important role in dengue severity. 
 
Laboratory diagnosis of dengue virus infection 
 
       Dengue diagnosis can be performed through virus isolation, 
genome and antigen detection and serological studies. Since easily 
available and rather cheap with fair amount sensitivity and specificity 
serological studies are the most applied methods in treating hospitals. 
Virus isolation and genome studies are done in research institutes. 
Different diagnostic tests can only be done at a particular time frame of 
the disease. 
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Networking of laboratories in India 
Since India is an endemic country for dengue and there has been 
recurrent breakouts a efficient network of specialized laboratories are 
required both detection during epidemics as well as for sentinel 
monitoring. For this the Government of India has setup a network of 
laboratories both sentinel surveillance hospitals and apex referral 
laboratories since 2007. ARLs have advanced diagnostic facilities for 
back support and serotonin of dengue samples and sends regularly to 
district level/ state level authorities for proper implementation of 
preventive measures. 
 
       For confirmation of dengue the government of India recommends 
ELISA based antigen detection test on first day and for ELISA antibody 
detection test for IgM after 5 days of the disease16. 
  
Serological diagnosis 
        The serological tests are done to detect either antigens or 
antibodies and ELISA is the most common applied test.  
 
IgM based assays 
        The detection of dengue IgM is a useful diagnostic test. in primary 
infection the IgM antibodies are detected starting from the fifth day of the 
disease but can detected as early as 3rd day. IgM may appear earlier in 
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secondary dengue infection but titers will be lesser.17 IgM ELISA tests 
have a sensitivity of 90% and specificity of 98% if taken 5 days after 
onset of illness. The dengue antigen used for antibody detection is the 
dengue protein E antigens of all 4 serotypes. Because the antibody is 
present in blood for atleast 3 months, its presence may not be diagnostic 
in current illness. For current infection a seroconversion of 4 fold or 
higher in paired sera is required. 
 
        Rapid diagnostic tests for IgM are now available which can be used 
as bedside tests. Most of these tests use recombinant antigens from all 4 
serotypes  and particle agglutination or lateral flow 
immunochromatographic strips. Results are available within 15 to 90 
minutes. They have sensitivity of 21-99% and specificity of 77-98%. 
 
IgG based assays 
        IgG based assays are mainly done to detect past infections. It is 
also done to differentiate from a primary and secondary infection of 
dengue. IgM/IgG ratio is a better index for detection primary infection 
where the ratio will be always greater than one whereas in a send art 
dengue the ratio will be less than one. 
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Neutralisation test 
        It is the most specific and sensitive serological test for dengue 
viruses and is used for determining the immune protection. The common 
protocol used is the serum dilution plaque neutralisation test. It is highly 
expensive and time consuming, hence not routinely done. 
 
 Virus detection 
        Dengue virus is present in blood 2 to 3 days prior to illness and 4 to 
5 days after. Whole blood, serum or plasma can be used for virus 
extraction. Virus is heat labile and hence must be transported in 4 degree 
Celsius for short period or at -70 degrees for longer storage. Mosquito 
inoculation is the best sensitive method for dengue virus isolation but it 
requires great technical skill and special containment so cell culture is 
preferred. Commonly used cell cultures are Vero cells, LLCMK2, 
BHK21. 
 
Antigen detection-NS1 based assays 
         NS1 is a non-structural protein  and is required for virus viability. 
It is secreted in both membrane bound forms and secreted forms. It can be 
detected by using ELISA at an early part of the clinical illness. But in 
case of dengue secondary infection there will be high titre of IgG 
antibodies that will neutralise the NS1 antigen hence will give poor 
outcome.18Many rapid diagnostic test kits for NS1 have been developed 
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and has been judiciously I areas of dengue break out but the sensitivity of 
the test is only 66% . 
  
Polymerase Chain Reaction 
       The advantage of PCR is than it can detect the virus from small 
samples. The procedure include extraction of nucleic acid, amplification 
of nucleic acid and finally detection of the amplified product. There are 
different types of PCR techniques like RT-PCR, nested RT-PCR, one-
step multiplex RT-PCR, real time RT-PCR. These tests are good enough 
to detect all the serotypes of dengue. Real time RT-PCR is much better as 
it involves only one step and does not require electrophoresis as required 
by other PCR tests. 
 
Clinical features 
           The incubation period is around 4 to 7 days. The disease spectrum 
varies from  asymptomatic cases to mild febrile illness to severe forms 
with DHF or DSS and also MODS. The disease has three phases 
 
1. Febrile phase 
2. Critical phase 
3. Recovery phase 
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           The febrile phase starts with high grade fever with prodromal 
symptoms such as facial flushing, skin erythema, headache, myalgia, 
arthralgia, retro-orbital pain, sore throat, pharyngeal congestion, 
conjunctival redness, loss of appetite, nausea, vomiting. Mild 
haemorrhagic manifestations like petechiae, mucosal membrane bleeding 
from nose  and gums. 19Tourniquet test is positive during this time. Liver 
may be enlarged and tender. 
 
        The critical phase lasts for another 5 days where fever subsides. 
Increased capillary permeability is the hall mark of this stage. Seriousness 
of the illness depends upon the severity of the plasma leakage. Warning 
signs during the critical phase include abdominal pain and tenderness, 
persistent vomiting, serositis, mucosal bleeding, tiredness, hepatomegaly, 
increase in hematocrit with fall in platelet count. Blood work during this 
time also shows decreased total count, elevated liver enzymes, decreased 
protein and albumin. 
 
         The recovery phase occurs usually 2 to 3 days of critical phase. The 
patient if gets better his general condition improves, there will be slow 
reabsorption. The appetite improves, hemodynamic status becomes 
normal. Bradycardia is common and some develop a petechiae rash and 
mild pruritus. WBC count improves and platelets also rises slowly. 
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          The criteria for discharge includes no fever for more than 48 hrs, 
improvement in general well being, normal vital signs, platelets more 
than 50,000 and rising trend, no bleeding manifestations. Healthy 
nutritious diet must be followed the replenish the catabolic state that the 
body has gone through. They should also be advised to take part in active 
vector control program so as to curb the infection rate. 
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Classification of DHF by WHO20 
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Assessing the severity of dengue 
 
 
 
Dengue shock syndrome 
     It is a type of Hypovolemic shock seen in dengue due to vascular 
permeability and plasma leakage causing displacement of intravascular 
fluid to leak third space. It has different spectrum like compensated 
shock, Hypovolemic shock, hypotension shock and cardiac arrest. 
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Signs of DSS 
 
1) coolness, pallor  and delayed capillary refill time 
2) CVS- low SBP, high DBP, and narrow pulse pressure 
3) Kidneys- reduced urine output 
4) GIT- vomiting and pain abdomen 
5) CNS- altered sensorium, restlessness 
6) RS- increased respiratory rate 
 
       Inadequate perfusion leads to tissue hypoxia and increased 
anaerobic glycolysis leading to production of lactic acidosis. The 
condition if not reversed at this stage will go on to refractory shock. 
Lactic acid is a myocardial depressant and will lead low cardiac output 
and cardiomyopathy. Other complications like DIC and MODS will 
ensue and death occurs by cardiac arrest. 
 
Other Manifestations of Dengue 
    Dengue infection sometimes can have atypical presentations and 
may lead to misdiagnosis or delayed diagnosis. 
1) GIT-  hepatitis and liver cell failure, acalculous cholecystitis, 
pancreatitis, acute abdominal pain 
2) CNS- Acute encephalitis, GBS 
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3) Haemophagocytic syndrome- Due to overt activation of T cells 
causing cytokine storm causing immense plasma leakage leading to cell 
death, progressive cytopenia and MODS. 
4) Renal- asymptomatic proteinuria, nephrotic range proteinuria, 
acute renal failure. 
 
Management of dengue 
 There is no specific treatment for dengue fever and fluid therapy is 
the best treatment for dengue. Symptomatic and supportive measures can 
prevent mortality and morbidity provided they are started at early stage. 
 
            Domiciliary management of dengue, which can be done in more 
than 80% of cases includes 
 
1. Adequate bed rest 
2. Tepid sponging 
3. Antipyretics like paracetamol 500 mg q6 
4. Oral rehydration solutions like WHO formulated ORS or fruit 
juices, maintain good hydration 
5. Monitoring for any complications during the critical phase. 
6. Taking adequate measures to prevent spread of dengue by 
using mosquito nets or repellents. 
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     Most of the cases of dengue can be managed at home, but some 
require hospital admission and careful monitoring and accurate 
intravenous fluid management. 
 
Criteria for admissions are: 
 
1) DF with warning signs and symptoms 
2) Significant bleeding from any site 
3) Hypotension 
4) Persistent high grade fever 
5) Rapid fall of platelet count 
6) Sudden drop in temperature  
7) Evidence of organ involvement 
8) High risk groups 
 
High risk groups are 
1) Infancy and pregnancy 
2) Elderly or obesity 
3) Peptic ulcer disease 
4) G6PD deficiency/Thalassemia 
5) Coronary artery disease 
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6) Chronic diseases such as COPD, bronchial asthma, diabetes,  
         hypertension 
7) Patients on steroids, anticoagulants , anti-platelets. 
8) Immunocompromised patients 
 
Treatment of DHF 
 
For DHF grade 1 and 2, close monitoring of vitals and hematocrit 
and platelets is needed along with adequate hydration using IV fluids, 
crystalloids are preferred. 
Any sign of deterioration should be picked up early and hypotension or 
renal failure requires treatment similar to DHF 3/4. 
 
Management of DHF grade 3 and 4 
 
1. Vitals monitoring especially BP, HCT, and platelet count. 
2. IV fluids with close monitoring of urine output and BP. 
3. Colloids, of BP does not pick up even after 1 litre of fluid 
challenge of crystalloids. 
4. Blood transfusion preferably whole blood, one in case of 
severe bleeding or in case of sudden drop of HCT. It is given 
at the rate of 10 ml/kg/hr. 
5. O2 is found to be beneficial in all patients in shock even if 
they have no respiratory distress 
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6. Platelet transfusion if needed 
7. Testing for other organ involvement like liver function test, 
renal function test. 
 
Fluid requirement can be calculated by Holiday and Segar formula 
 
  Amount of fluid that should be given needs to be maintenance plus 
fluid lost by dehydration 
 
Maintenance fluid for body weight  
For less than 10 kg -  100ml per kg 
For 10-20 kg -             1000ml + 50 ml/kg body weight exceeding 10 kg 
More than 20 kg-        1500ml + 20ml/kg body weight exceeding 20 kg 
 
Fluid lost by dehydration is taken as 5% or 50 ml / kg. 
 
The fluid chosen for resuscitation is usually crystalloid and then 
colloids. Both have similar efficacy. Crystalloids, normal saline is the 
choice, but to prevent hyperchloremic acidosis Ringers’ lactate is used as 
follow up. 
 
When there is blood loss more than 10% of total volume or if there 
is refractory shock whole blood transfusion is indicated at the rate of 
10ml/kg. Platelet transfusion is indicated irrespective of platelet count if 
28 
 
there is bleeding. It is indicated when the platelet count is less than 
10,000 in absence of bleeding. 
 
Prevention and control 
 
      Since dengue has become a major public health concern and has 
become a pandemic and there is no definite treatment other than 
supportive treatment, the golden rule of prevention is better than cure 
applies here. 
 
Vector control 
Aedes mosquitoes are the primary carries and amplifiers of dengue, 
to control the disease the strings should be pulled to reduce the vector 
load i.e. the mosquitoes. We have altered the environment and made it 
comfortable breeding grounds for mosquitoes. The Aedes mosquitoes lay 
eggs on fresh water sources and there plenty of man made sources to lay 
eggs and flourish. 
 
 
 
Unless there is effective vector control the disease cannot be 
controlled. Destroying the breeding places should be done first. 
Insecticides are recommended for vector control during epidemics as well 
in endemic areas. Use of personal protective methods like long clothes 
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and use of mosquito repellents such as picaridin, DEET, IR3535 is also 
encouraged. 
 
Dengue vaccine 
Although not yet commercially available so many dengue vaccines 
are under trial and  would be available in the near future. Some of them 
are Sarnoff Pasteur's CYD vaccine, DENVax, TV003/TV005, TDENV 
PIV, virus like particles using Pichia pastoris. 
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MATERIAL AND METHODS 
 
      The study was conducted at the department of Internal Medicine, 
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai 600003. 
 
ETHICAL COMMITTEE APPROVAL 
Obtained 
 
PATIENT CONSENT  
Obtained 
 
DURATION OF STUDY 
6 months 
 
STUDY DESIGN 
Observational study 
 
SAMPLE SIZE  
100 patients 
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INCLUSION CRITERIA 
Patients 
1) Age group 18-60 years  
2) Diagnosed as Dengue fever by IgM Elisa 
 
 
EXCLUSION CRITERIA 
• Pregnant women 
• Other causes of fever 
• Acute calculous cholecystitis 
• Chronic liver disease 
• Chronic kidney disease 
• Congestive cardiac failure 
• Post cholecystectomy 
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DATA COLLECTION AND METHODS 
 
Patients are subjected to detailed history taking and clinical 
examination and valid laboratory investigations. 
Patients admitted with Dengue fever diagnosed by IgM Elisa - 
selected for clinical study as per inclusion / exclusion criteria are 
subjected to routine blood investigations like complete hemogram, renal 
function tests, liver function test and ultrasonogram of abdomen. Detailed 
history taking and clinical examination will be done. Patients with 
Dengue fever will be analyzed for following factors  
            -Age 
            -Sex 
            -Bleeding manifestations 
            -Pulse, Blood pressure 
            -Total count, Platelet count and Hematocrit 
            -Measurement of gallbladder thickness by ultrasound 
            -Presence of perinephric fluid collection 
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Patients diagnosed as Dengue fever by IgM Elisa will undergo 
ultrasound abdomen for the measurement of gallbladder wall thickness 
and it will be correlated with the severity of the disease. 
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STATISTICAL ANALYSIS 
 
The results are analysed using SPSS software version 21. 
Association between variables was analysed using chi-square test. 
 
The primary efficacy changes were the increase gall bladder 
thickness with severity of thrombocytopenia, bleeding manifestations, 
tachycardia, hypotension, deranged liver enzymes, renal failure all which 
would assess the severity of dengue and so a comparison was made 
between gall bladder wall thickness and disease severity. 
 
Statistical significance is assumed with a p value of less than 0.005 
 
SPONSORSHIP 
No 
 
CONFLICT OF INTEREST 
None 
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OBSERVATION AND RESULTS 
 
Age group in years 
 
 
 
                 
Percentage
18-20 yrs
21-30 yrs
31-40 yrs
41-50 yrs
51-60 yrs
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
18-20 17 17.0 17.0 17.0 
21-30 21 21.0 21.0 38.0 
31-40 31 31.0 31.0 69.0 
41-50 18 18.0 18.0 87.0 
51-60 13 13.0 13.0 100.0 
Total 100 100.0 100.0  
 Valid 
Male 
Female 
Total 
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Gender 
Frequency Percent Valid Percent
43 43.0 43.0 
57 57.0 57.0 
100 100.0 100.0 
GENDER
 
Cumulative 
Percent 
43.0 
100.0 
 
 
MALE
FEMALE
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PULSE 
Pulse Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Normal 81 81.0 81.0 81.0 
 Abnormal 19 19.0 19.0 100.0 
 Total 100 100.0 100.0  
 
 
 
 
 
 
Percentage
Normal
Abnormal
 BP 
 Normal 
 Hypotension
 Total 
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BLOOD PRESSURE 
Frequen
cy 
Percent Valid Percent
71 71.0 71.0 
 29 29.0 29.0 
100 100.0 100.0 
Blood pressure
 
Cumulative 
Percent 
71.0 
100.0 
 
 
Normal
Hypotension
Thrombocytopenia
Valid Normal
 Mild
 Moderate
 Severe
 Very Severe
 
Life 
Threatening
 Total
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THROMBOCYTOPENIA 
 
Frequenc
y 
Percent 
Valid 
Percent
 1 1.0 1.0 
 16 16.0 16.0 
 21 21.0 21.0 
 38 38.0 38.0 
 12 12.0 12.0 
 
12 12.0 12.0 
 100 100.0 100.0
Thrombocytopenia
Normal
Mild
Moderate
Severe
Very severe
Life Threatening
 
Cumulative 
Percent 
1.0 
17.0 
38.0 
76.0 
88.0 
100.0 
  
 
40 
 
Hematocrit/ PCV 
HCT/PCV Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
Low 47 47.0 47.0 47.0 
Normal 47 47.0 47.0 94.0 
High 6 6.0 6.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
 
 
HCT/PCV
Low
Normal
High
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BLOOD UREA 
Blood Urea Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
< 40 76 76.0 76.0 76.0 
> 40 24 24.0 24.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
 
 
 
UREA
<40 normal
>40 abnormal
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SERUM CREATININE 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
< 1 86 86.0 86.0 86.0 
> 1 14 14.0 14.0 100.0 
Total 100 100.0 100.0   
 
 
 
 
 
 
Serum creatinine
<1
>1
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TOTAL BILIRUBIN 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
< 1 91 91.0 91.0 91.0 
> 1 9 9.0 9.0 100.0 
Total 100 100.0 100.0  
 
 
 
  
Total bilirubin
<1
>1
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PERINEPHRIC COLLECTION 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
Present 17 17.0 17.0 17.0 
Absent 83 83.0 83.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
 
 
perinephric collection
Present
Absent
45 
 
SGOT 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
< 200 40 40.0 40.0 40.0 
> 200 60 60.0 60.0 100.0 
Total 100 100.0 100.0  
 
 
  
SGOT
<200
>200
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GALL BLADDER WALL THICKNESS 
GBWT Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
<= 3 31 31.0 31.0 31.0 
4-6 62 62.0 62.0 93.0 
>= 7 7 7.0 7.0 100.0 
Total 100 100.0 100.0  
 
 
  
GBWT
<=3mm
4-6mm
>7mm
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BLEEDING MANIFESTATION 
Bleeding Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
Yes 30 30.0 30.0 30.0 
No 70 70.0 70.0 100.0 
Total 100 100.0 100.0  
 
 
 
  
Bleeding manifestations
Yes
NO
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Comparison of Age groups and GBWT 
 Age Group in 
years 
  GB Wall Thickness  
Total 
  
 
P value 
  <= 3 4-6 >= 7 
18-20 
  
  
  
  
Count 4 10 3 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.33 
% 
within 
Age 
Group 
in years 
23.5% 58.8% 17.6% 100.0% 
% 
within 
GB 
Wall 
Thickne
ss 
12.9% 16.1% 42.9% 17.0% 
  
21-30 
  
  
Count 4 16 1 21 
% 
within 
Age 
19.0% 76.2% 4.8% 100.0% 
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Group 
in years 
% 
within 
GB 
Wall 
Thickne
ss 
12.9% 25.8% 14.3% 21.0% 
  
31-40 
  
  
  
  
Count 9 21 1 31 
% 
within 
Age 
Group 
in years 
29.0% 67.7% 3.2% 100.0% 
% 
within 
GB 
Wall 
Thickne
ss 
29.0% 33.9% 14.3% 31.0% 
  Count 9 8 1 18 
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41-50 
  
  
  
  
% 
within 
Age 
Group 
in years 
50.0% 44.4% 5.6% 100.0% 
% 
within 
GB 
Wall 
Thickne
ss 
29.0% 12.9% 14.3% 18.0% 
  
51-60 
  
  
  
  
Count 5 7 1 13 
% 
within 
Age 
Group 
in years 
38.5% 53.8% 7.7% 100.0% 
% 
within 
GB 
Wall 
16.1% 11.3% 14.3% 13.0% 
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Thickne
ss 
Total 
  
  
Count 31 62 7 100 
% 
within 
Age 
Group 
in years 
31.0% 62.0% 7.0% 100.0% 
% 
within 
GB 
Wall 
Thickne
ss 
100.0% 100.0% 100.0% 100.0% 
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There was not much significance of comparison of GBWT with 
different age groups except in youngest age group were there is a slight 
high incidence of increase in gall bladder wall thickness. 
 
 
 
Age Group in years
51-60
41-50
31-40
21-30
11-20
Co
u
n
t
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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Comparison of gender and GBWT 
  
  GB Wall Thickness Total 
  
P value 
  <= 3 4-6 >= 7 
Gender 
  
  
  
  
  
Male 
  
  
Count 12 28 3 43  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.89 
% 
within 
Gender 
27.9% 65.1% 7.0% 100.0% 
% 
within 
GB 
Wall 
Thickne
ss 
38.7% 45.2% 42.9% 43.0% 
Female 
  
  
Count 19 34 4 57 
% 
within 
Gender 
33.3% 59.6% 7.0% 100.0% 
% 
within 
GB 
Wall 
61.3% 54.8% 57.1% 57.0% 
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Thickne
ss 
Total 
  
  
Count 31 62 7 100 
% 
within 
Gender 
31.0% 62.0% 7.0% 100.0% 
% 
within 
GB 
Wall 
Thickne
ss 
100.0% 100.0% 100.0% 100.0% 
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No significant association was found between gender and gall 
bladder thickness. 
 
 
 
 
Gender
FemaleMale
Co
u
n
t
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
56 
 
 
   GB Wall Thickness Total  
P value 
    <= 3 4-6 >= 7   
Pulse Normal Count 31 50 0 81  
Less 
than 
0.001 
    % 
within 
Pulse 
38.3% 61.7% .0% 100.0% 
    % 
within 
GB 
Wall 
Thickne
ss 
100.0% 80.6% .0% 81.0% 
  Abnorm
al 
Count 
0 12 7 19 
    % 
within 
Pulse 
.0% 63.2% 36.8% 100.0% 
    % 
within 
GB 
.0% 19.4% 100.0% 19.0% 
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Wall 
Thickne
ss 
Total Count 31 62 7 100 
  % 
within 
Pulse 
31.0% 62.0% 7.0% 100.0% 
  % 
within 
GB 
Wall 
Thickne
ss 
100.0% 100.0% 100.0% 100.0% 
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There was high significance between abnormal pulse i.e. 
tachycardia and GBWT. The pulse rate was more abnormal in patients 
with higher gall bladder thickness. 
 
 
 
Pulse
AbnormalNormal
Co
u
n
t
60
50
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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COMPARISON OF BLOOD PRESSURE AND GBWT 
  GB Wall Thickness Total P 
value 
  <= 3 4-6 >= 7  
Blood 
Pressure 
Normal Count 
29 40 2 71 
 
  % within 
Blood 
Pressure 
40.8% 56.3% 2.8% 
100.0
% 
 
  % within 
GB Wall 
Thickness 
93.5% 64.5% 28.6% 71.0% 
0.001 
 Abnormal Count 2 22 5 29  
  % within 
Blood 
Pressure 
6.9% 75.9% 17.2% 
100.0
% 
 
  % within 
GB Wall 
Thickness 
6.5% 35.5% 71.4% 29.0% 
 
Total Count 31 62 7 100  
 % within 
Blood 
Pressure 
31.0% 62.0% 7.0% 
100.0
% 
 
 % within 
GB Wall 
Thickness 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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There was significant association which shows that as the gall 
bladder wall thickening increases there is chance to go into hypotension 
or shock. 
 
 
Blood Pressure
AbnormalNormal
Co
u
n
t
50
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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PLATELET COUNT AND GBWT 
   GB Wall Thickness Total 
  
P value 
    <= 3 4-6 >= 7 
Platelet 
Count 
Normal Count 
0 1 0 1 
 
    % within 
Platelet 
Count 
.0% 100.0% .0% 100.0% 
 
    % within 
GB Wall 
Thickness 
.0% 1.6% .0% 1.0% 
 
  Mild Count 12 4 0 16 <0.001 
    % within 
Platelet 
Count 
75.0% 25.0% .0% 100.0% 
 
    % within 
GB Wall 
Thickness 
38.7% 6.5% .0% 16.0% 
 
  Moderate Count 14 7 0 21  
    % within 
Platelet 
66.7% 33.3% .0% 100.0% 
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Count 
    % within 
GB Wall 
Thickness 
45.2% 11.3% .0% 21.0% 
 
  Severe Count 5 33 0 38  
    % within 
Platelet 
Count 
13.2% 86.8% .0% 100.0% 
 
    % within 
GB Wall 
Thickness 
16.1% 53.2% .0% 38.0% 
 
  Very Severe Count 0 10 2 12  
    % within 
Platelet 
Count 
.0% 83.3% 16.7% 100.0% 
 
    % within 
GB Wall 
Thickness 
.0% 16.1% 28.6% 12.0% 
 
  Life 
Threatening 
Count 
0 7 5 12 
 
    % within .0% 58.3% 41.7% 100.0%  
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Platelet 
Count 
    % within 
GB Wall 
Thickness 
.0% 11.3% 71.4% 12.0% 
 
Total Count 31 62 7 100  
  % within 
Platelet 
Count 
31.0% 62.0% 7.0% 100.0% 
 
  % within 
GB Wall 
Thickness 
100.0% 100.0% 100.0% 100.0% 
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There was high significance in the association between the level of 
thrombocytopenia and the increase in GBWT. As the platelet count falls 
the gall bladder wall thickness increases. Gall bladder thickness is more 
than when there critical fall in level of platelets to life threatening level. 
 
 
 
Platelet Count
Life
 Threatening
V
ery
 Severe
Severe
M
oderate
Mild
N
orm
al
Co
u
n
t
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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Haematocrit (PCV) and GBWT comparison 
   GB Wall Thickness Total P value 
    <= 3 4-6 >= 7   
PCV Low Count 22 25 0 47  
    
% within 
PCV 
46.8% 53.2% .0% 
100.0
% 
 
    
% within 
GB Wall 
Thickness 
71.0% 40.3% .0% 47.0% 
 
  
Nor
mal 
Count 9 35 3 47 
<0.001 
    
% within 
PCV 
19.1% 74.5% 6.4% 
100.0
% 
 
    
% within 
GB Wall 
Thickness 
29.0% 56.5% 42.9% 47.0% 
 
  High Count 0 2 4 6  
    
% within 
PCV 
.0% 33.3% 66.7% 
100.0
% 
 
    
% within 
GB Wall 
.0% 3.2% 57.1% 6.0% 
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Thickness 
Total Count 31 62 7 100  
  
% within 
PCV 
31.0% 62.0% 7.0% 
100.0
% 
 
  
% within 
GB Wall 
Thickness 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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          There was high significance statistically during comparison of 
HCT/PCV with GBWT, suggesting that there is higher plasma leakage 
with increasing GBWT causing elevated HCT levels. 
  
PCV
HighNormalLow
Co
u
n
t
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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COMPARISON OF BLEEDING MANIFESTATIONS AND GALL 
BLADDER WALL THICKNESS 
  GB Wall Thickness Total P 
value 
  <= 3 4-6 >= 7  
Bleeding 
Manifestat
ions 
Yes Count 1 22 7 30 
 
 
  
% within 
Bleeding 
Manifestat
ions 
3.3% 73.3% 23.3% 
100.0
% 
 
  
% within 
GB Wall 
Thickness 
3.2% 35.5% 
100.0
% 
30.0%  
 No Count 30 40 0 70 
<0.00
1 
  
% within 
Bleeding 
Manifestat
ions 
42.9% 57.1% .0% 
100.0
% 
 
  % within 96.8% 64.5% .0% 70.0%  
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GB Wall 
Thickness 
Total Count 31 62 7 100  
 
% within 
Bleeding 
Manifestat
ions 
31.0% 62.0% 7.0% 
100.0
% 
 
 
% within 
GB Wall 
Thickness 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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          The comparison showed high statistical significance, meaning that 
there was high incidence of bleeding or DHF when the gall bladder 
thickness was more than or equal to 7mm. 
 
 
 
 
Bleeding Manifestations
NoYes
Co
u
n
t
50
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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COMPARISON OF SERUM UREA WITH GBWT 
  GB Wall Thickness Total 
P value 
  <= 3 4-6 >= 7  
Blood 
Urea 
< 40 Count 30 46 0 76  
  
% 
within 
Blood 
Urea 
39.5% 60.5% .0% 100.0%  
  
% 
within 
GB Wall 
Thickne
ss 
96.8% 74.2% .0% 76.0%  
 > 40 Count 1 16 7 24  
  
% 
within 
Blood 
Urea 
4.2% 66.7% 29.2% 100.0% <0.001 
  
% 
within 
3.2% 25.8% 100.0% 24.0%  
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GB Wall 
Thickne
ss 
Total Count 31 62 7 100  
 
% 
within 
Blood 
Urea 
31.0% 62.0% 7.0% 100.0%  
 
% 
within 
GB Wall 
Thickne
ss 
100.0% 100.0% 100.0% 100.0%  
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There was significant statistical outcome for the comparison, which 
suggests that the increased GBWT which is a measure of plasma leakage 
can cause renal failure as suggested by elevated urea levels. 
 
 
 
Blood Urea
> 40< 40
Co
u
n
t
50
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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COMPARISON OF SERUM CREATININE WITH GBWT 
   GB Wall Thickness Total 
P value 
    <= 3 4-6 >= 7   
Serum 
Creatinine 
< 1 Count 31 53 2 86  
    
% within 
Serum 
Creatinine 
36.0% 61.6% 2.3% 100.0%  
    
% within 
GB Wall 
Thickness 
100.0% 85.5% 28.6% 86.0%  
  > 1 Count 0 9 5 14 <0.001 
    
% within 
Serum 
Creatinine 
.0% 64.3% 35.7% 100.0%  
    
% within 
GB Wall 
Thickness 
.0% 14.5% 71.4% 14.0%  
Total Count 31 62 7 100  
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% within 
Serum 
Creatinine 
31.0% 62.0% 7.0% 100.0%  
  
% within 
GB Wall 
Thickness 
100.0% 100.0% 100.0% 100.0%  
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          This comparative study showed high statistical significance, similar 
to the one with blood urea level, suggesting that increase in GBWT is 
associated with a high incidence in renal failure. 
 
 
 
 
Serum Creatinine
> 1< 1
Co
u
n
t
60
50
40
30
20
10
0
GB Wall Thickness
<= 3
4-6
>= 7
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COMPARISON BETWEEN TOTAL BILIRUBIN AND GBWT 
   GB Wall Thickness Total 
P value 
    <= 3 4-6 >= 7   
Bilirubi
n 
< 1 Count 31 56 4 91  
    
% 
within 
Bilirubi
n 
34.1% 61.5% 4.4% 100.0%  
    
% 
within 
GB 
Wall 
Thickne
ss 
100.0% 90.3% 57.1% 91.0%  
  > 1 Count 0 6 3 9  
    
% 
within 
Bilirubi
n 
.0% 66.7% 33.3% 100.0% 0.002 
    % .0% 9.7% 42.9% 9.0%  
78 
 
within 
GB 
Wall 
Thickne
ss 
Total Count 31 62 7 100  
  
% 
within 
Bilirubi
n 
31.0% 62.0% 7.0% 100.0%  
  
% 
within 
GB 
Wall 
Thickne
ss 
100.0% 100.0% 100.0% 100.0%  
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There is statistical significance with the comparison of GBWT with 
total bilirubin suggesting that there is high incidence of liver cell failure 
with increase in GBWT 
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> 1< 1
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COMPARISON OF GBWT AND PERINEPHRIC COLLECTION 
   GB Wall Thickness Total 
P value 
    <= 3 4-6 >= 7   
Perinephri
c 
Collection 
Present Count 0 10 7 17  
    
% within 
Perinephri
c 
Collection 
.0% 58.8% 41.2% 100.0%  
    
% within 
GB Wall 
Thickness 
.0% 16.1% 100.0% 17.0% <0.001 
  Absent Count 31 52 0 83  
    
% within 
Perinephri
c 
Collection 
37.3% 62.7% .0% 100.0%  
    
% within 
GB Wall 
Thickness 
100.0% 83.9% .0% 83.0%  
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Total Count 31 62 7 100  
  
% within 
Perinephri
c 
Collection 
31.0% 62.0% 7.0% 100.0%  
  
% within 
GB Wall 
Thickness 
100.0% 100.0% 100.0% 100.0%  
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          There is high statistical significance in the comparative data 
suggestive that increased GBWT is associated with severe plasma 
leakage as evidenced by perinephric collection. 
 
 
 
Perinephric Collection
AbsentPresent
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COMPARISON OF GBWT AND SGOT 
   GB Wall Thickness Total 
P value 
    <= 3 4-6 >= 7   
SGOT < 200 Count 19 21 0 40  
    
% 
within 
SGOT 
47.5% 52.5% .0% 100.0%  
    
% 
within 
GB 
Wall 
Thickn
ess 
61.3% 33.9% .0% 40.0%  
  > 200 Count 12 41 7 60  
    
% 
within 
SGOT 
20.0% 68.3% 11.7% 100.0% 0.003 
    
% 
within 
GB 
Wall 
38.7% 66.1% 100.0% 60.0%  
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Thickn
ess 
Total Count 31 62 7 100  
  
% 
within 
SGOT 
31.0% 62.0% 7.0% 100.0%  
  
% 
within 
GB 
Wall 
Thickn
ess 
100.0% 100.0% 100.0% 100.0%  
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> 200< 200
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COMPARISON BETWEEN SGPT AND GBWT 
   GB Wall Thickness Total 
P value 
    <= 3 4-6 >= 7   
SGPT < 200 Count 19 21 0 40  
    
% 
within 
SGPT 
47.5% 52.5% .0% 100.0%  
    
% 
within 
GB 
Wall 
Thickn
ess 
61.3% 33.9% .0% 40.0% 0.003 
  > 200 Count 12 41 7 60  
    
% 
within 
SGPT 
20.0% 68.3% 11.7% 100.0%  
    
% 
within 
GB 
Wall 
38.7% 66.1% 100.0% 60.0%  
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Thickn
ess 
Total Count 31 62 7 100  
  
% 
within 
SGPT 
31.0% 62.0% 7.0% 100.0%  
  
% 
within 
GB 
Wall 
Thickn
ess 
100.0% 100.0% 100.0% 100.0%  
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          Comparison between both SGPT and SGOT with GBWT showed 
statistical significance suggesting that more plasma leakage is associated 
with liver injury. 
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DISCUSSION 
        Dengue is a vector borne disease that has caused recurrent epidemics 
throughout the world. This study was conducted was conducted at the 
time of the epidemic in 2016. A similar epidemic occurred in 2015 which 
caused a great deal of mortality and morbidity throughout the country. 
The study was done in a tertiary government hospital where at the time 
most of the attention was given to the recent dengue breakout. And since 
it was higher referral centre most of the cases were already either 
diagnosed or were in poor condition that required urgent medical 
attention. 
        The most crucial part of treatment of dengue is the monitoring of the 
critical phase of dengue. This part is crucial that the patient may be 
asymptomatic to begin but will be having early features of plasma 
leakage. Only if the plasma leakage is early diagnosed can the disease be 
prevented from going for further complications. Once complications sets 
in dengue has a high mortality rate. 
        The critical phase of dengue fever is closely monitored by blood 
investigations mainly haematocrit and platelet count. This is a laborious 
task especially at the time of epidemic where the laboratories will be 
over-flooded. Research has been underway since many years for better, 
faster methods of assessing plasma leakage. One of the practical approach 
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is the assistance of radiological techniques namely ultrasound to detect 
serositis i.e. seepage of fluid in spaces lining internal organs. Many 
studies have revealed the importance of gall bladder wall thickening in 
dengue. Although acalculous cholecystitis is a part of dengue spectrum of 
diseases, the increase in gall bladder thickness has been found to correlate 
to the severity of plasma leakage. There has been proven study in many 
journals and research centres where they used serial ultrasound to assess 
the gall bladder wall thickness and found out that it is a reliable method to 
assess disease severity and plasma leakage. Also there have been reports 
of other signs of serositis such as pleural effusion, perinephric fluid 
collection and perihepatic fluid collection to have helped in assessing 
status of dengue fever. 
           In the current study onetime assessment of 100 patients of 
confirmed dengue fever was done with signs of bleeding, vitals, complete 
blood count, liver function test, renal function test and ultrasound for gall 
bladder wall thickness. 
         The date was compiled and using statistical tools were analysed. 
The current was almost in par with the observations of similar studies 
done outside. 
Comparing the different variables of the study revealed the 
importance of gall bladder thickness. 
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Age groups and gender did not give much statistical significance 
when compared with gall bladder wall thickness. Only observation was 
that it was slightly more in younger population. Vitals like pulse and 
blood pressure were greatly deranged when it came to gall bladder wall 
thickness of 7 and above. This is backed up by statistical significance 
hence proves that plasma leakage is directly proportional to gall bladder 
wall thickness. 
It was also noted that bleeding manifestations was also higher in 
cases of gall bladder wall thickness more than 7mm. This helps in 
monitoring for gall bladder wall thickness in stable patients to detect 
whether they are having increasing thickness which suggest that they high 
chance of bleeding. Early diagnosis of DHF can be done by following 
this test. 
The increased gall bladder wall thickness also pointed to high 
incidence of multi organ damage as evidenced by the increase in blood 
urea, serum creatinine, total bilirubin, liver enzymes. All these variables 
have statistical significance in comparative data analysis. Also to be 
noted is the incidence of perinephric collection in select patients who had 
bleeding manifestations, multiorgan failure and shock all suggestive that 
this may be a finding associated with severe dengue. 
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The low platelet count and high haematocrit was directly 
proportional to gall bladder thickness, and showed statistical significance. 
This would mean gall bladder wall thickening can be used as a method of 
assessing plasma leakage along with haematocrit and platelet count. This 
will reduce the number of needle pricks, the lesser number of infection 
spread, and much lesser need of laboratory assistance. 
The study also had various short comings. The study was done in a 
tertiary hospital so the study group included mostly severe dengue 
infected patients who were referred from primary or secondary care 
hospitals. This might caused a greater number of people who were in the 
extreme zone of to have been included in the study. Also many patients 
are on domiciliary treatment for dengue and could not be include in the 
study. The laboratory values can also can have its share of errors which 
can also affect a part of the study. A follow up study was not included 
which would have thrown more light as to aspects of how many the 
variables would have shifted further more in the course of time. 
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CONCLUSION 
             From the study, it has come into conclusion that gall bladder wall 
thickness is a significant contributor to assessment of plasma leakage and 
hence the severity of dengue. Many authorised studies have backed up 
this observation. The main advantage of this method is that it a fast and 
easily approachable method and can be easily practised in most centres. 
With this added tool the monitoring of dengue patients become more 
comprehensive and hopefully can used to curb the onset dengue 
associated complications like dengue shock syndrome. Many other tools 
for better assessment of dengue severity and monitoring are in research so 
are research for vaccines and drugs. Hopefully all these will ensure that 
the morbidity and mortality of dengue and controlled and someday the 
disease itself be brought into control. 
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